---
document_datetime: 2023-09-21 22:20:35
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sogroya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: sogroya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.8187551
conversion_datetime: 2025-12-22 10:29:10.622162
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sogroya

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                      |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------|
| X/0006/G             | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 25/05/2023                          | 24/07/2023                                  | SmPC, Labelling and PL           | Refer to the scientific discussion: EMEA/H/C/005030/X/0006/G |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10920 /202208   | Periodic Safety Update EU Single assessment - somapacitan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/03/2023   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| II/0004/G             | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile) B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the | 24/11/2022   | n/a   |                                     |
| PSUSA/10920 /202202   | Periodic Safety Update EU Single assessment - somapacitan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/09/2022   | n/a   | PRAC Recommendation - maintenance   |
| IB/0003/G             | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                                                                                                               | 04/07/2022   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                |            |            |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| X/0001/G            | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 24/02/2022 | 25/04/2022 | SmPC, Labelling and PL |                                   |
| PSUSA/10920 /202108 | Periodic Safety Update EU Single assessment - somapacitan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/04/2022 | n/a        |                        | PRAC Recommendation - maintenance |